There is no greater killer worldwide than cardiovascular disease (CVD). According to WHO reports, every year it causes an estimated 17.9 million deaths globally. That’s 31% of all deaths every year.
In recent years, the medical field has seen a rise in demand for cardiac monitoring products. This demand, paired with improvements in technology have opened up opportunities for monitor advancements.
As the founder of Kerrisdale Capital, I have made research on developing biotechnology one of our main focuses. In this article, I, Sahm Adrangi, will discuss the growing demand for cardiac monitoring devices and its impact on the industry.
Improvements in cardiac technology.
Many years ago, you may have associated cardiac monitoring devices as something that was bulky and disruptive. Outdated technologies were inconvenient while adhesive electrodes were cumbersome and irritating.
Not only have devices improved over time, but better use of materials and tech has made them less expensive to produce. Some new advancements feature wireless connectivity, real-time monitoring, and patient ability to flag specific events. New advancements can also record longer periods of cardiac activity while easing the transition of care from hospital to home.
Impact on the industry.
As urbanization increases, so do sedentary lifestyles and consumption of high-calorie foods. All contributing factors for CVD. Thus, contributing to the need for cardiac monitoring technology that minimize the chance of infection and improve the efficiency of these devices.
Industry experts and market forecasts reveal that the market for cardiac monitors are expected to grow nearly 5.2% in the next 4 years. Alternatively, stringent regulatory procedures and high costs associated with monitoring could restrain growth of the global cardiac market in the same forecast period.
The ups and downs of a competitive landscape.
The presence of a number of large, medium, and small outfits contribute to an exceptionally fragmented and focused market.
A substantial share of the global cardiac monitoring market is made up of multinational players. While various companies and organizations focus on various growth strategies, including partnerships, collaborations, new product launches, and geo-focused expansion to enhance their presence.
This competitive landscape has both its ups and downs. As with any industry, some are merely capitalizing on open opportunities in the market while others have real value to offer patients with improved technology.
Sahm Adrangi – Final thoughts on cardiac monitoring advancements.
It’s no secret that the cost of healthcare is inherently rising in the industrialized world. As it does, there is a shift from traditional “response-driven” care to prediction-based preventative care. Of course, growing demands and technological advances leave space for manufacturers to capitalize and improve the field.
At Kerrisdale Capital, we focus on investigative research into a variety of companies, including those participating in the growth of the cardiac monitor industry. I, Sahm Adrangi, publish this research to inform the public of our findings and why we believe that these companies will have success or fail. As Sahm Adrangi, a short activist at Kerrisdale Capital, I feel it is our duty to help others understand subjects that may be misunderstood in the market.
About the Author: Sahm Adrangi of Kerrisdale Capital
Founder and CIO of Kerrisdale Capital, Sahm Adrangi is an activist and published researcher. In recent years, Kerrisdale has developed expertise in the biotechnology and telecommunications sectors. Adrangi also shares his firm’s view on stocks, with an emphasis on overhyped shorts and under-followed longs. As part of Kerrisdale’s broader education efforts, Mr. Adrangi has met with the DCC and filed ex parties.